Nordic Nanovector ASA
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Nordic Nanovector ASA
Shrinking cash and COVID-19 uncertainty have prompted Nordic Nanovector to slash costs and focus purely on its lead asset’s pivotal trial in third-line follicular lymphoma.
Novartis's Jakavi joins the likes of Roche's Actemra in targeting the life-threatening immune reaction which is killing acutely ill COVID-19 patients.
This week's announcements include changes at the top of Johnson & Johnson, Roche, Pierre Fabre, Nordic Nanovector, Inthera Bioscience and the Dementia Discovery Fund, plus new board appointments at Dova, Easton, Destiny Pharma and Abivax.
Appointments: Celgene, Hikma Pharmaceuticals, Silence Therapeutics, Sosei, BioNTech, Nordic Nanovector And Axcella Health Announce New Hires
Companies announcing executives moves this week include Celgene with a new CFO, Hikma Pharmaceuticals, Silence Therapeutics, Sosei, BioNTech, Nordic Nanovector, Axcella Health, and NDA Group. The British Generic Manufacturers Association also announced a new chair.
- Radiopharmaceuticals, Contrast Agents
- Large Molecule
- Other Names / Subsidiaries
- Nordic Nanovector GmbH
- Nordic Nanovector Limited